IL10 and ulcerative colitis: As expected, the VK2 administration substantially alleviated the ulcerative colitis, and it was mainly by decreasing the DAI index, increasing the expression of anti-inflammatory factor IL-10, muc2, and tight junction proteins (ZO-1, occludin), and by improving the intestinal tissue architecture.